Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OY9L
|
|||
| Former ID |
DNCL002572
|
|||
| Drug Name |
ALXN6000
|
|||
| Synonyms |
Samalizumab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Alexion Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane glycoprotein OX2 (CD200) | Target Info | . | [3] |
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00648739) Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM. U.S. National Institutes of Health. | |||
| REF 3 | American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.